Decentralized Trials: The Value Of Direct-To-Patient And Pharmacy-Led Solutions

Geographic inaccessibility and site logistics remain among the most persistent obstacles to clinical trial enrollment, particularly for patients in remote or underserved regions. A pharmacy-led direct-to-patient (DTP) model addresses this directly: by shipping investigational products from a centralized, GMP-compliant pharmacy to patients' homes, you can broaden participation, reduce site burden, and maintain the cold chain integrity that traditional site-based handoffs put at risk.

The FDA's 2024 Guidance on Conducting Clinical Trials with Decentralized Elements explicitly recognizes DTP as a mechanism for reaching underrepresented populations, and the operational case is equally compelling. Centralizing inventory at a single pharmacy location reduces waste, eliminates redundant shipments, and gives sponsors real-time control over supply distribution. Pharmacist oversight adds a critical layer of safety review, including checks for drug interactions and dosing errors, that can catch issues before product ever reaches a patient.

Choosing between a site-to-patient model and a pharmacy-driven approach requires weighing regulatory licensing complexity, protocol timing, blinding requirements, and site readiness. This article walks you through both models, their trade-offs, and the best practices, from contingency planning to data privacy protocols, that determine DTP success. Download now to build a DTP strategy that improves patient access without sacrificing compliance or supply chain control.